In summary, the identification of genetic signatures for the various FTLD subtypes has great value for genetic counselling and correct diagnosis. In addition, this knowledge could aid strategic planning for future tailored therapeutic approaches that target disease-specific pathogenetic mechanisms in this orphan disease.
converging evidence from recent literature suggests that some distinctive clinical features might help in driving neurology practice in molecular diagnostics. This issue was addressed by Van Langenhove and colleagues in their new study. 3 In a large, well-characterized FlandersBelgian cohort, Van Langenhove et al. evaluated patients with the recently identified repeat expansion in the C9orf72 gene, with the aim of identifying differences in clinical presentation when compared with patients carrying MAPT or GRN mutations and patients without known pathogenetic mutations. 3 A large body of literature has described patients with either MAPT or GRN mutations, but few reports to date have defined the picture of C9orf72-related disease.
The authors found that patients with C9orf72 repeat expansion usually had an early disease onset and a family history of FTLD and/or FTD-MND, and they commonly presented with bvFTD with a disinhibited phenotype and MND as an early feature. 3 By contrast, GRN mutation carriers more often presented with bvFTD, avPPA and concomitant CBS symptoms at onset while MAPT mutation carriers had mainly bvFTD presentation. Interestingly, parkinsonism was common, later in the disease course, in all types of genetic FTLD and in patients with no known mutation, and psychosis could be present in any sporadic and genetic cases of FTLD except for those caused by MAPT mutations.
Van Langenhove et al. propose a diagnostic algorithm based on analysis of the described distinctive clinical features, which might be very helpful on clinical grounds. 3 Considering these three genes, C9orf72 genetic screening should have priority in patients with FTD-MND, as well as in cases where a genetic svPPA is suspected. Conversely, GRN mutations should be initially taken into account in avPPA or CBS phenotypes. In keeping with previous litera ture, MAPT mutations usually manifest with bvFTD and also need to be con sidered in the PSP pheno type. This algorithm should not only apply for famili al cases, but may also be considered for patients with apparently sporadic FTLD.
Along with the above-reported distinctive clinical features, the pattern of brain atrophy might be helpful in differential diagnosis of genetic forms of FTLD. Patients carrying MAPT mutations usually show symmetrical brain atrophy involving mainly the temporal lobes, whereas patients with GRN mutations more often have an asymmetric pattern of atrophy with fronto parietal involvement. 
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Accumulating evidence suggests that statin therapy could assist functional recovery following acute ischaemic stroke. A recent study indicates that early administration of statins after intravenous thrombolysis for stroke improves functional outcomes, and reduces mortality and neurological deterioration. Owing to the observational study design, however, these findings should be interpreted cautiously. Ischaemic stroke is the leading cause of serious disability and a major cause of mortality worldwide. 1 Treatment options for patients presenting with ischaemic stroke are limited, however. Only recombinant tissue plasminogen activator (tPA), admini stered within 3 h after onset of ischaemic stroke symptoms, is approved by the FDA, and few patients are eligible to receive this treatment. A recent nonrandomized observational analysis of patients enrolled in an Italian acute stroke registry, the THRombolysis and Statins (THRaST) study, has provided preliminary evidence that administration of statins within 72 h of thrombolytic treatment is safe and might improve neurological outcomes. 2 Chronic treatment with statins, which are hydroxymethylglutaryl coenzyme A (HMGCoA) reductase inhibitors, was previously shown to reduce the risk of recurrent stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, 3 and interest has been growing in the potential for statins to improve functional outcomes when used after stroke. Expanding experimental and clinical evidence indicates that-by reducing downstream products of the HMG-CoA pathway other than cholesterol, including isoprenoids-statins have beneficial effects on endothelial function, cerebral blood flow, inflammation and haemostasis. In rodent models of acute ischaemic stroke, statins have been shown to reduce neuronal injury and infarct size and improve behavioural recovery. 4 Potential haemorrhagic risks associated with statins have created controversy over their use for stroke treatment. Chronic atorva statin use was associated with increased risk of intracerebral haemorrhage in SPARCL, 3 and some meta-analyses found evidence that statins increase the risk of haemorrhagic conversion of ischaemic stroke after thrombolysis. 5 Conversely, findings in animal studies indicate that statins might extend the therapeutic window of thrombo lytics when co-administered. 6 The recent THRaST study aimed to address these conflicting findings. 2 In THRaST, a multicenter consortium of investigators in Italy collected treatment and outcomes data on 2,072 patients with ischaemic stroke who were treated with intravenous tPA within the 3 h time window. Patients were divided into 'statin' and 'no statin' groups: the statin group (n = 839, 40.5%) was defined as those who received statins within 72 h of thrombolysis, and the no statin group (n = 1,233, 59.5%) was defined as those who did not receive statins within 72 h, irrespective of whether they had been treated with statins prior to stroke (n = 63) or never before (n = 1,170). Several short-term (7-day) and long-term (90-day) efficacy and safety end points were evaluated.
After adjustment for several potential confounding factors, the statin group was found to be more likely to have neurological improvement at 7 days (OR 1.68, 95% CI 1.26-2.25), and were less likely to have neurological deterioration (OR 0.31, 95% CI 0.19-0.53) compared with the no statin group. The statin group was also more likely to have a good functional outcome (Modified Rankin Scale score <2) at 90 days (OR 1.63, 95% CI 1.18-2.26). Risk of sympto matic intra cerebral haemorrhage was not increased by statin treatment, although these analyses were probably limited by the small number of haemorrhages in both groups (1.2% of patients in the statin group versus 3.8% in the no statin group). Mortality was lower in the statin group (5.8%) versus the no statin group (15.1%). The investigators concluded that statins could benefit both short-term and long-term outcomes after thrombolytic-treated ischaemic stroke.
The results of THRaST are consistent with recent meta-analyses of the effects of prior treatment with statin therapy on functional outcomes and mortality after ischaemic stroke. 7 In the largest of these meta-analyses, statin treatment at the time of stroke was associated with a 41% increase in the chance of a good functional outcome (Modified Rankin Scale score 0-2). The results are also consistent with animal studies that suggest that statins can be administered safely and lead to im provement in functional outcomes. 8 Strengths of the THRaST analysis include the large number of patients studied, the multicentre design, and the opportunity to explore multiple statin formulations, doses and time windows for delivery of treatment. Notably, the results at 3 months showed that early initiation of statin therapy, within 24 h of thrombolysis, was associated with 88% increased chance of excellent outcomes, whereas statin treatment after this time had a less marked beneficial effect. This suggestion of an increased benefit with earlier administration of statins is consistent with findings in preclinical studies. 4 One limitation of THRaST was its inability to fully exclude the possibility of a protective effect of statins against recurrent stroke, which could explain some of the apparent effect on longer-term functional outcomes. The main limitation of the study, however, as readily acknowledged by the investigators, is its nonrandomized, nonblinded design. Statins were not administered to patients with certain characteristics that were also likely to be associated with outcomes: atrial fibrillation and greater stroke severity, for example, were more common in patients in the no statin group. In effect, patients with larger embolic infarcts might have been least likely to be treated with statins. Although analyses were adjusted for these probably confounding factors, residual confounding by these and other factors associated with the decision to treat with statins might have occurred.
Ultimately, determination of whether statins should be administered acutely after stroke-and the optimal time, route of administration, and dose-will require completion of randomized clinical trials. Some preliminary randomized trials have already provided evidence of benefit of statins on functional outcomes. In one pilot study, for example, investigators randomly assigned 60 patients with acute ischaemic stroke within 12 h of stroke onset to 40 mg simvastatin daily for 7 days followed by 20 mg daily for up to 90 days, versus placebo. Statistically significant improvement in the NIH Stroke Scale score was seen as early as 3 days after treatment initiation, but this improvement did not persist at 90 days. 9 Recent dose-escalation trials have also found that short-term administration of statins at doses higher than that currently approved is probably safe in patients with stroke, and this strategy is being further investigated in ongoing trials. 10 The findings from THRaST add to the growing literature on the safety and potential benefit of statin treatment in the setting of acute ischaemic stroke. Whether all patients with acute ischaemic stroke who receive thrombolysis should receive statins soon after stroke onset, however, remains a question that can only be answered with a suitably designed randomized clinical trial. 
''
Dopamine-based therapies are the standard treatment for Parkinson disease (PD) as they can effectively control motor symptoms, allowing most patients to maintain a reasonable quality of life during the early, 'honey moon' stages. With disease progression, how ever, the response to dopamine replacement therapy becomes less consistent and less predictable, and drug-induced dyskinesias are experienced by the majority of patients.
1 Deep brain stimulation (DBS) of the sub thalamic nucleus (STN) 2 or globus pallidus internus (GPi) 3 has been used for treatment of a subset of patients with PD for over 20 years. In a recent report of the EARLYSTIM trial, published in the New England Journal of Medicine, 4 Schuepbach and colleagues tested the hypothesis that a combination of medical therapy and neurostimulation during early-stage disease can improve quality of life over medical therapy alone in patients with PD.
Several trials in patients with PD have established that GPi and/or STN stimulation provides long-term improvement of levodopa-responsive symptoms (including tremor, rigidity and bradykinesia) in addition to improvement of motor fluctuations and drug-induced dyskinesia. 5, 6 Notably, these trials involved only patients who had advanced PD, with an average disease duration of 10-13 years. As this disease advances, work and social activities and quality of life become com promised, and cognitive and psychi atric comorbidities are common. A need exists, therefore, for earlier in tervention strategies.
The current study 4 comprised a multicentred, randomized trial to compare DBS plus best medical management with best medical management alone, 7 and involved 251 patients with early-stage PD (Hoehn and Yahr stage <3). All participants had short duration of motor complications (<3 years) and some impairment in activities of daily living (ADLs) or mildto-moderate impairment in social and occupational functioning. 4 Notably, only patients under the age of 60 years were enrolled. The primary outcome was defined as the mean change in quality of life from baseline up to 2 years post randomization, assessed using the 39-item Parkinson Disease Questionnaire (PDQ-39).
The researchers found that combined neurostimulation and medical therapy was superior to medical therapy alone: compared with baseline, neurostimulation was associated with a 26% improvement in quality of life (PDQ-39 summary index score) at 24 months, whereas medical therapy alone was associated with a 1% decline over the same period. Furthermore, compared with medical therapy alone, early neurostimulation was associated with greater improvements in motor scores (assessed using the Unified Parkinson Disease Rating Scale III [UPDRS-III]), ADLs and mobility time, as well as with greater reductions in levodopa-related motor complications (assessed using UPDRS-IV) and levodopa-equivalent dosage of medication (Box 1).
A major strength of the study by Schuepbach et al. 4 is that best medical ther apy was in keeping with expert medical manage ment of early PD, and an indepen dent panel of experts ensured that each patient received appropriate care. An important weakness, however, is that the patients could not be blinded to their assigned therapy.
Use of quality of life as a primary outcome measure provides a global assessment of effects that are of importance to patients, but this subjective measure can be influenced by the patients' expectations of their assigned treatment. For example, individuals who are assigned to the surgical '' …neurostimulation was associated with a 26% improvement in quality of life … at 24 months… ''
